E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Grass-pollen induced rhinoconjunctivitis (hay fever). |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine whether sublingual immunotherapy with grass allergen tablet suppresses nasal symptoms after experimental nasal provocation with grass pollen extracts and to determine whether this protection persists for at least 1 year after discontinuation of treatment. |
|
E.2.2 | Secondary objectives of the trial |
To assess clinical outcomes with regard to symptom alleviation during the grass pollen season, during treatment and for 1 year after discontinuation. To assess the mechanisms by which sublingual immunotherapy may or may not induce tolerance. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients must meet all of the following criteria to be eligible to participate in this study: 1. Adults age 18 to 65 years. 2. A clinical history of grass pollen-induced allergic rhinoconjunctivitis for at least 2 years with peak symptoms in May, June, or July. 3. A clinical history of moderate - severe rhinoconjunctivitis symptoms interfering with usual daily activities or with sleep sleep as defined according to the ARIA classification of rhinitis. 4. A clinical history of rhinoconjunctivitis for at least 2 years requiring treatment with either antihistamines or nasal corticosteroids during the grass pollen season. 5. Positive skin prick test response, defined as wheal diameter greater than or equal to 3 mm, to Phleum pratense. 6. Positive specific IgE, defined as greater than or equal to IgE class 2 (0.7 kU/L) , against Phleum pratense. 7. A positive response to nasal allergen challenge with Phleum pretense, defined as an increase in TNSS greater than or equal to 7 points above baseline. 8. For women of childbearing age, a willingness to use an effective form of contraception for the duration of the trial. 9. The ability to give informed consent and comply with study procedures. |
|
E.4 | Principal exclusion criteria |
Patients must not meet any of the following criteria to be eligible to participate in this study: 1. Prebronchodilator FEV1 less than 70% of predicted value at either screening or baseline visit. 2. A clinical history of moderate - severe allergic rhinitis , as defined according to the ARIA classification of rhinitis, due to tree pollen near or overlapping the grass pollen season. 3. A clinical history of asthma requiring regular inhaled corticosteroids for > 4 weeks per year outside of the grass pollen season. 4. A clinical history of moderate-severe allergic rhinitis as defined according to the ARIA classification of rhinitis caused by an allergen to which the participant is regularly exposed. 5. History of emergency visit or hospital admission for asthma in the previous 12 months. 6. History of chronic obstructive pulmonary disease. 7. History of significant recurrent acute sinusitis, defined as 2 episodes per year for the last 2 years, all of which required antibiotic treatment. 8. History of chronic sinusitis, defined as a sinus symptoms lasting greater than 12 weeks that includes 2 or more major factors or 1 major factor and 2 minor factors. Major factors are defined as facial pain or pressure, nasal obstruction or blockage, nasal discharge or purulence or discolored postnasal discharge, purulence in nasal cavity, or impaired or loss of smell. Minor factors are defined as headache, fever, halitosis, fatigue, dental pain, cough, and ear pain, pressure, or fullness. 9. History of systemic disease affectiong the immune system such as autoimmune diseases, immune complex disease or immunodeficiency. 10. At randomisation, current symptoms of, or treatment for, upper respiratory tract infection, acute sinusitis, acute otitis media, or other relevant infectious processÍž serous otitis media is not an exclusion criterion. Participants may be reevaluated for eligibility after symptoms resolve. 11. At randomization, inflammatory conditions in the oral cavity with severe symptoms such as oral lichen planus with ulcerations or severe oral mycosis. 12. Active malignancy at randomization. 13. Any tobacco smoking within the last 6 months or a history of greater than or equal to 10 pack years. 14. Previous treatment by immunotherapy with grass pollen allergen within the previous 5 years. 15. Any history of grade 4 anaphylaxis due to any causes as defined by the WAO grading criteria for immunotherapy (see appendix 7 of the protocol). 16.A history of allergy to vertebrate/finned fish with, if positive, an associated elevated positive skin test (or elevated specific IgE) to vertebrate/finned fish. 17. History of bleeding disorders or treatment with anticoagulation therapy. 18. History of anti-IgE monoclonal antibody treatment. 19. Ongoing systemic immunosuppressive treatment. 20. History of intolerance to the study therapy, rescue medications, or their excipients. 21. For women of childbearing age a positive serum or urine pregnancy test with sensitivity of less than 50 mIU/mL within 72 hours before the start of study therapy. 22. The use of any investigational drug within 30 days of the screening visit. 23. The presence of any medical condition that the investigator deems incompatible with participation in the trial. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The nasal response to allergen challenge at 3 years. This is defined as the average of the Total Nasal Symptom Score (TNSS) Area Under the Curve (AUC) measured at 0 to 1 hours and the AUC measured at 1 to 10 hours after allergen challenge. The primary endpoint consists of the comparison of [sublingual immunotherapy + subcutaneous immunotherpay placebo] versus [sublingual immunotherapy placebo + subcutaneous immunotherapy placebo]. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Explore mechanisms of immunotherapy |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of trial is last patient last visit in the study. Duration of clinical trial is 4 years (March 2011 to March 2015). A further year is required for mechanistic assays until March 2016. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |